Immune thrombocytopenia (ITP) is an autoimmune disease characterized by an isolated decrease in platelet count and an increased risk of bleeding. The pathogenesis is complex, affecting multiple components of the immune system and causing both peripheral destruction of platelets and inadequate production in the bone marrow. In this article, we review the treatment of ITP from a historical perspective, discussing first line and second line treatments, and management of refractory disease.
No takes yet. Share an insight, caveat, or question.
Martínez‐Carballeira et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: